Chronic diseases and depression often go hand in hand. There is a growing evidence-base that shows how exercise can help reduce depressive symptoms in people with chronic illness and it’s encouraging to see a steady stream of primary research being published in this area. A new ancillary study published in JAMA examines the effect that [read the full story…]
The reduced life expectancy (15-20 years less) often faced by many people with schizophrenia is frequently a result of cardiovascular disease. Lifestyle choices (smoking, lack of exercise and poor diet) can increase the risk of these diseases, but people who take antipsychotic drugs often have the additional problem of weight gain that is caused by [read the full story…]
A year ago this week I blogged about a study in the British Journal of Psychiatry that showed the dramatically reduced life expectancy of people with severe mental illness, who on average live 15-20 years less than the rest of the population. Twelve months on and a new study published in the same journal paints an equally [read the full story…]
NICE have published public health guidance and a new care pathway to help people of South Asian origin who are living in England to stop using traditional South Asian varieties of smokeless tobacco. These publications are focused on people with ancestral links to Bangladesh, India, Nepal, Pakistan or Sri Lanka and smokeless tobacco products such [read the full story…]
Weight gain is one of the side effects that people who take antipsychotic drugs complain of the most. Obesity is common in this population and this can often lead to cardiovascular problems and a far shorter life expectancy than the rest of the population. As a result, there is a great deal of interest in [read the full story…]
There is an increasing body of evidence showing that depression and anxiety are linked with other health conditions like cancer and cardiovascular disease. I’ve blogged about the link between depression and stroke, and there are a number of other studies that show an association between psychological distress (the symptoms of depression and anxiety) and mortality, [read the full story…]
Back in February, I blogged about a cohort study published in the New England Journal of Medicine, which concluded that ADHD drugs are not linked with an increased risk of serious cardiovascular events. The last few years has seen heated debate about the use of central nervous stimulants in children and young people. The lack [read the full story…]
NICE published a clinical guideline on the treatment and management of depression in adults with chronic physical health problems in 2009. This new evidence update refreshes that guidance by searching for new systematic reviews and randomised controlled trials on the subject and summarising them in a short (16 page) document. The authors searched a range [read the full story…]
A number of concerns have arisen over recent years about the safety of the various drugs used to treat ADHD (Attention Deficit Hyperactivity Disorder) in children and young adults. These central nervous system stimulants include methylphenidate, dexmethylphenidate, dextroamphetamines, amphetamine salts, atomoxetine and pemoline. Case reports have highlighted that sudden cardiac death can be brought on [read the full story…]
Read this important new research if you work in mental health or public health and have an interest in the relationship between mental disorders and adversity in childhood and chronic physical conditions in later adult life. The cross sectional study was conducted by researchers in New Zealand who set out to investigate whether childhood adversities [read the full story…]
